Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027627 (metastases)
 103,950 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Two hundred forty-two patients who had bronchial carcinoma and who underwent radical surgery were studied in order to determine putative host resistance to the tumor at histologic level, i.e., lymphocytic infiltration in the center and around the tumor, together with sinus histiocytosis and follicular hyperplasia in the regional lymph nodes. These features were evaluated in a semiquantitative way, giving rise to three groups of patients: D- (reaction absent or poor), D+ (reaction present), and D++ (strong reaction present). Five-year survival rates and the incidence of metastases in regional nodes were significantly related to the putative host resistance against the tumor, but no clear-cut correlation between grade of malignancy of the tumor and histologic type was evidenced. The significance of these reactive changes is fully discussed.
 ...
PMID:Histology of bronchial carcinoma and regional lymph nodes as putative immune response of the host to the tumor. 83 42

One hundred consecutive patients with findings suggestive of resectable bronchogenic carcinoma were studied prospectively to determine if routine liver, brain, and bone scans (multiorgan scans) detected metastases which were not suggested by a history, physical examination, and serum chemistries. Multiorgan scans were compared with clinical evaluations in 52 patients found to have operable bronchogenic carcinoma. There was a discordance between scans and clinical evaluations in 25/153 scans (16 per cent). Two of the 22 negative scans in patients with abnormal clinical findings were false negative. Sixteen of the 17 positive scans in patients with normal clinical findings were false positive. One of the 131 scans done in patients with no evidence of metastases on clinical evaluation was true positive. These data indicate that the routine use of multiorgan scans in the initial staging of potentially resectable bronchogenic carcinoma is not justified.
 ...
PMID:Multiorgan scans for staging lung cancer. Correlation with clinical evaluation. 85 Apr 23

Cardiac metastases from bronchogenic carcinoma are not commonly diagnosed prior to death. This study isolates factors associated wtih the development of cardiac involvement. Four hundred eighteen consecutive patients with lung cancer who had autopsies were studied. Twenty-five percent of these patients had cardiac involvement. Factors associated with cardiac metastases were (1) histologic cell type of the tumor, (2) aggressive therapy, (3) extent of disease, and (4) tumor differentiation. The presence of cardiac metatases was not related to the length of survival. Clinical signs of cardiac involvement included an enlarging heart on the chest x-ray film, development of congestive heart failure, or electrocardiographic changes. Suspicion of cardiac metastases in high-risk individuals, prompt diagnostic evaluation, and rapid institution of therapy may improve the outlook for many patients, since reaccumulation of fluid was generally slow.
 ...
PMID:Cardiac metastases in lung cancer. 85 38

Paraneoplastic neurologic syndromes in patients suffering from bronchial carcinoma were found by Croft and Wilkinson (Croft et al. 1965, Croft and Wilkinson 1965) in 16%. We examined the question whether in patients suffering from bronchial carcinoma neurologic syndromes are as frequent as in a comparative group of patients with different bronchial diseases. Out of 99 patients 61 had histological proof of bronchial carcinoma, 38 were suffering from chronic inflammatory bronchial diseases. The groups were statistically comparable to each other. Cases with carcinoma in situ (TINOMO) showed no significant difference from patients without bronchial carcinoma. In patients who showed intrathoracic metastases of lymphatic ganglions we found neurologic syndromes in 31% (p less than 0.01). Differing from the extension of tumor metastases there was no correlation between duration and frequency of neurologic syndromes. This corresponds to the experience of our hospital in the last 10 years; 5.7% of all patients with extracerebral tumors showed neurologic syndromes, most frequently polyneuropathies. In 10-15% of a normal population one can find these symptoms (Skre 1972), this means they are polygenetic. We did not find frequently an oat cell carcinoma in our material. Cases in which the neuromyopathy preceeded the manifestation of the bronchial carcinoma were not seen. Altogether it can be stated that paraneoplastic neuromyopathies in patients suffering from bronchial carcinoma are more seldom than it was to be assumed from the anglo-saxon literature.
 ...
PMID:[Bronchial carcinoma and paraneoplastic neuromyopathy]. 85 14

A brief survey of bibliography on heart and pericardial metastases resulting from bronchial carcinoma is followed by a report on our autopsy findings in 110 patients suffering from bronchial carcinoma. In 29 cases, i.e. 26 p.c., heart and pericardial metastases were found. In three cases, only the heart was affected, in 16 cases only the pericardium, and in 10 cases both heart and pericardium were involved. In 27 cases, they were spread by way of the blood and were mostly part of a general formation of hematogenous metastases. In-growth exclusively from primary tumour regions was found only in two cases. In 19 cases, metastases were both hematogenous and grown-in per continuitatem. Anatomicopathologically, 18 patients had a small cell carcinoma, 10 a squamous cell carcinoma, and one showed an adenocarcinoma. While 15, i.e. 14%, of our 110 patients, on whom we performed an autopsy, had died from arrosion bleeding, this was true only in one case in the group of 29 patients with heart and pericardial metastases. Radiation side effects in the form of lung and pericardial fibroses in the patients, who had generally been treated with cobalt 60 gamma rays, were confirmed by autopsy findings only in one third in both cases as compared with the findings by X-ray diagnosis during life. Lung fibroses were found in 16 cases (14%), and pericardial fibroses in 6 cases (5.5%). They were not strictly dependent on the dose.
 ...
PMID:[Heart and pericardial metastases resulting from bronchial carcinoma. Side effects of radiotherapy (author's transl)]. 87 67

The inoperable bronchial carcinoma tends to early formation of metastases. If the tumor responds well to different cytostatic drugs, chemotherapy is absolutely necessary. In this case, combined therapy has better results than monotherapy. We use chemotherapy prior to radiotherapy in order to prevent hematogenic extension of the disease and to ameliorate the receptiveness of the primary tumor. In order to avoid local recurrence it is necessary to submit the primary tumor and the mediastinum to radiotherapy. A focal dose of 3000 rd within three weeks is considered to be sufficient. This dose generally does not cause severe myelosuppression, so that the chemotherapy can be continued. A report is given on the provisional results of different chemotherapeutic combinations. Further studies, however, are absolutely necessary in order to be in a position to give recommendations of common validity.
 ...
PMID:[Integrated treatment of the inoperable bronchial carcinoma (author's transl)]. 91 99

Bony metastases in association with a lesion in the lung are usually regarded as secondary to bronchial carcinoma. This is generally true when the metastases are osteolytic. However, in the presence of a solitary lung lesion with osteoblastic metastases, the diagnosis of bronchial carcinoid should be considered. The following case illustrates this point.
 ...
PMID:Bronchial carcinoid with osteoblastic metastases. 92 95

The authors report 21 cases of pulmonary metastases from operated cases of rectal and colonic carcinoma. Half the patients were aged between 60 and 70 years. In all cases except one the primary tumour was known and treated surgically before the metastasis occurred. The authors emphasize the necessity of radiological supervision of the chest after operation and recall that neither chemotherapy nor radiotherapy should be undertaken without prior histological confirmation. It is possible to remove the metastases by surgery but a high percentage require pneumonectomy i.e. it is necessary to take the same precautions before operation as for primary carcinoma of the bronchus. The operative mortality was nil, and the five year survival rate 18 p. 100.
 ...
PMID:[Surgical treatment of pulmonary metastases from rectocolic cancers. Apropos of 21 cases]. 93 17

The results of major pulmonary resection in 58 patients greater than 70 years of age were reviewed. The histological distribution and extent of nodal metastases in this age group are the same as in younger patients. The absolute five-year survival rate for the 55 patients undergoing curative resection was 30% (17 patients). It was 36% (11 patients) for those patients with squamous cell carcinoma and 22% (5 patients) for those with adenocarcinoma. The operative mortality was only 14% (8 patients). Of the 49 patients treated by lobectomy, 17 lived five years or more free of disease, whereas none of the 6 patients treated by pneumonectomy survived five years. The five-year survival rate of 30% in this series of elderly patients treated by major pulmonary resection makes resections in such patients with bronchogenic carcinoma worthwhile.
 ...
PMID:Major pulmonary resection for bronchogenic carcinoma in the elderly. 98 55

Twenty-one patients with advanced metastatic cancer received amphotericin B (AmB) plus BNUC in a Phase I chemotherapy trial. Of 11 patients with measurable metastases from bronchogenic carcinoma, five had partial antitumor responses lasting 1.5 to 12+ months, and one had objective improvement. Only two of six patients with other types of tumors had objective improvement of short duration. No consistent evidence of immunologic stimulation was observed in eight patients studied. These results suggest that amphotericin B may increase the therapeutic ratio of BCNU, and further trials of this new concept in chemotherapy of advanced tumors are in progress. The dose-limiting toxicity was myelosuppression, usually thrombocytopenia. No enhancement of BCNU toxicity by the addition of AmB was observed. The recommended dose for future studies is: AmB, 7.5 mg/m2 on day 1, 15 mg/m2 on day 1, 30 mg/m2 on days 3 and 4; plus BCNU, 250 mg/m3 on day 4. The regimen is repeated every 6 to 8 weeks.
 ...
PMID:Amphotericin B plus 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU-NSC no. 409962) in advanced cancer. Phase I and preliminary phase II results. 99 Nov 5


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>